| Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ... Nature communications 10 (1), 2674, 2019 | 273 | 2019 |
| Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution LG Karacosta, B Anchang, N Ignatiadis, SC Kimmey, JA Benson, ... Nature communications 10 (1), 5587, 2019 | 178 | 2019 |
| Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells AM Gocher, G Azabdaftari, LM Euscher, S Dai, LG Karacosta, TF Franke, ... Journal of Biological Chemistry 292 (34), 14188-14204, 2017 | 102 | 2017 |
| A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression LG Karacosta, BA Foster, G Azabdaftari, DM Feliciano, AM Edelman Journal of Biological Chemistry 287 (29), 24832-24843, 2012 | 98 | 2012 |
| DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity B Anchang, KL Davis, HG Fienberg, BD Williamson, SC Bendall, ... Proceedings of the National Academy of Sciences 115 (18), E4294-E4303, 2018 | 48 | 2018 |
| Nucleoporin 62 and Ca2+/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells LG Karacosta, LA Kuroski, WA Hofmann, G Azabdaftari, M Mastri, ... The Prostate 76 (3), 294-306, 2016 | 23 | 2016 |
| Preclinical Analysis of JAA-F11, a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging LG Karacosta, JC Fisk, J Jessee, S Tati, B Turner, D Ghazal, R Ludwig, ... Translational oncology 11 (2), 450-466, 2018 | 15 | 2018 |
| Humanization of JAA-F11, a highly specific anti-thomsen-friedenreich pancarcinoma antibody and in vitro efficacy analysis S Tati, JC Fisk, J Abdullah, L Karacosta, T Chrisikos, P Philbin, S Morey, ... Neoplasia 19 (9), 716-733, 2017 | 15 | 2017 |
| Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge G Bouchard, FJ Garcia-Marques, LG Karacosta, W Zhang, A Bermudez, ... Cancer research 82 (4), 648-664, 2022 | 10 | 2022 |
| Comparative effectiveness of up to three lines of chemotherapy treatment plans for metastatic colorectal cancer I Toumazis, M Kurt, A Toumazi, LG Karacosta, C Kwon MDM Policy & Practice 2 (2), 2381468317729650, 2017 | 5 | 2017 |
| Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation FR Adler, ARA Anderson, A Bhushan, P Bogdan, JJ Bravo-Cordero, ... Cell systems 14 (4), 252-257, 2023 | 4 | 2023 |
| From imaging a single cell to implementing precision medicine: an exciting new era LG Karacosta Emerging Topics in Life Sciences, 2021 | 4 | 2021 |
| Individualized drug combination based on single-cell drug perturbations B Anchang, K Davis, H Fienberg, S Bendall, L Karacosta, G Nolan, ... Cancer Research 78 (13_Supplement), 2275-2275, 2018 | 1 | 2018 |
| Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single cell multidimensional analysis LG Karacosta, B Anchang, S Kimmey, M Rijn, JB Shrager, SC Bendall, ... Cancer Research 78 (13_Supplement), 4997-4997, 2018 | 1 | 2018 |
| Corrigendum to “Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis”[Neoplasia 19.9 (2017) 716-733] S Tati, JC Fisk, J Abdullah, L Karacosta, T Chrisikos, P Philbin, S Morey, ... Neoplasia (New York, NY) 20 (1), 118, 2018 | 1 | 2018 |
| CaMKK2 activates oncogenic Akt in ovarian cancer cells and is a promising therapeutic target AM Gocher, G Azabdaftari, L Karacosta, TF Franke, AM Edelman The FASEB Journal 30, 714.8-714.8, 2016 | 1 | 2016 |
| YAP1 defines a highly plastic, persister cell population in small cell lung cancer (SCLC) following relapse CA Stewart, SM Groves, R Wang, K Ramkumar, Y Xi, L Diao, AG Serrano, ... Cancer Research 84 (6_Supplement), 5864-5864, 2024 | | 2024 |
| Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry LG Karacosta, D Pancirer, JS Preiss, JA Benson, W Trope, JB Shrager, ... Scientific reports 13 (1), 21781, 2023 | | 2023 |
| Abstract LB_B05: Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level S Bhattacharyya, CA Stewart, AM Victorian, SF Ehsan, EF Lujan, A Duarte, ... Molecular Cancer Therapeutics 22 (12_Supplement), LB_B05-LB_B05, 2023 | | 2023 |
| Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level S Bhattacharyya, SF Ehsan, LG Karacosta Frontiers in Network Physiology 3, 1256104, 2023 | | 2023 |
